FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169466414> ?p ?o ?g. }

• W3169466414 endingPage "1292" @default.
• W3169466414 startingPage "1284" @default.
• W3169466414 abstract "Abstract Limited data are currently available regarding fibrosis progression after hepatitis C virus (HCV) eradication. The goal of the present study was to evaluate the effects of HCV eradication on liver stiffness measurements (LSMs), aspartate aminotransferase/platelet ratio index (APRI) scores, fibrosis‐4(FIB‐4) scores, chitinase‐3‐like protein 1 (CHI3L1) levels and Golgi protein 73 (GP73) levels in patients with chronic hepatitis C (CHC). One hundred and two patients who received direct antiviral agents (DAAs) therapy at Peking University First Hospital participated in the present study. Clinical information and serum samples were collected at baseline, at the end of treatment (EOT), and at the weeks 12, 24 and 48 after treatment (W12, W24 and W48, respectively). Of the 102 patients, 51 had mild‐to‐moderate fibrosis (F1/F2), and 51 had advanced fibrosis (F3/F4). The LSMs improved for all patients at the EOT, with observed changes of 2.85 kPa, and the decrease continued to W12. However, a more pronounced improvement was noted for the advanced fibrosis (F3/F4) patients, with a change of 3.6 kPa from baseline to the EOT. Significant decreases between the baseline and EOT measurements were observed in the APRI and FIB‐4 scores [0.64 (0.39–1.21) vs. 0.35 (0.26–0.52), p <0.001; 2.53 (1.30–3.91) vs. 1.87 (0.89–2.5), p <0.001], after which the values decreased until W12, with no significant difference observed. Serum CHI3L1 and GP73 levels were profoundly decreased at the EOT compared with those at baseline [134.07 (154.49) vs. 103.75 (98.04), p =0.025; 98.24 (64.76) vs. 88.91 (50.89), p =0.002]. DAA treatments could significantly improve liver fibrosis of CHC patients as evidenced by decreased liver stiffness, APRI scores and FIB‐4 scores. Improvements in liver fibrosis markers (especially serum CHI3L1 and GP73) were prominent in patients with advanced fibrosis, indicating that serum CHI3L1 and GP73 could be noninvasive markers for monitoring fibrosis in CHC patients. Significance Statement The prospective cohort evaluated the effect of direct antiviral agents (DAAs) on fibrosis regression after hepatitis C virus (HCV) eradication of Chinese people in the real‐world study. This study highlighted that rapid and significant fibrosis regression rather than reduction in inflammation was achieved with DAA treatment, and this regression could be detected as early as the end of treatment. We found the serum CHI3L1 and GP73 levels can be used to monitor changes in fibrosis in CHC patients." @default.
• W3169466414 created "2021-06-22" @default.
• W3169466414 creator A5005140056 @default.
• W3169466414 creator A5006012404 @default.
• W3169466414 creator A5012503019 @default.
• W3169466414 creator A5018759190 @default.
• W3169466414 creator A5028119955 @default.
• W3169466414 creator A5034168127 @default.
• W3169466414 creator A5040085560 @default.
• W3169466414 creator A5042258212 @default.
• W3169466414 creator A5044044186 @default.
• W3169466414 creator A5046262467 @default.
• W3169466414 creator A5050027379 @default.
• W3169466414 creator A5050463135 @default.
• W3169466414 creator A5069880463 @default.
• W3169466414 date "2021-06-20" @default.
• W3169466414 modified "2023-10-18" @default.
• W3169466414 title "Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication" @default.
• W3169466414 cites W1948038010 @default.
• W3169466414 cites W2011122771 @default.
• W3169466414 cites W2011235168 @default.
• W3169466414 cites W2023149416 @default.
• W3169466414 cites W2027498662 @default.
• W3169466414 cites W2049533426 @default.
• W3169466414 cites W2058592552 @default.
• W3169466414 cites W2063920699 @default.
• W3169466414 cites W2115885122 @default.
• W3169466414 cites W2117766751 @default.
• W3169466414 cites W2126552035 @default.
• W3169466414 cites W216121951 @default.
• W3169466414 cites W2164978310 @default.
• W3169466414 cites W2185218296 @default.
• W3169466414 cites W2515460802 @default.
• W3169466414 cites W2524249329 @default.
• W3169466414 cites W2598028107 @default.
• W3169466414 cites W2604711981 @default.
• W3169466414 cites W2736841222 @default.
• W3169466414 cites W2742618178 @default.
• W3169466414 cites W2743112891 @default.
• W3169466414 cites W2750659292 @default.
• W3169466414 cites W2755497792 @default.
• W3169466414 cites W2770543051 @default.
• W3169466414 cites W2902834632 @default.
• W3169466414 cites W2922106787 @default.
• W3169466414 cites W2973361123 @default.
• W3169466414 cites W2985534581 @default.
• W3169466414 cites W2990986307 @default.
• W3169466414 cites W2992772421 @default.
• W3169466414 cites W3091440471 @default.
• W3169466414 doi "https://doi.org/10.1111/jvh.13558" @default.
• W3169466414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34105867" @default.
• W3169466414 hasPublicationYear "2021" @default.
• W3169466414 type Work @default.
• W3169466414 sameAs 3169466414 @default.
• W3169466414 citedByCount "5" @default.
• W3169466414 countsByYear W31694664142022 @default.
• W3169466414 countsByYear W31694664142023 @default.
• W3169466414 crossrefType "journal-article" @default.
• W3169466414 hasAuthorship W3169466414A5005140056 @default.
• W3169466414 hasAuthorship W3169466414A5006012404 @default.
• W3169466414 hasAuthorship W3169466414A5012503019 @default.
• W3169466414 hasAuthorship W3169466414A5018759190 @default.
• W3169466414 hasAuthorship W3169466414A5028119955 @default.
• W3169466414 hasAuthorship W3169466414A5034168127 @default.
• W3169466414 hasAuthorship W3169466414A5040085560 @default.
• W3169466414 hasAuthorship W3169466414A5042258212 @default.
• W3169466414 hasAuthorship W3169466414A5044044186 @default.
• W3169466414 hasAuthorship W3169466414A5046262467 @default.
• W3169466414 hasAuthorship W3169466414A5050027379 @default.
• W3169466414 hasAuthorship W3169466414A5050463135 @default.
• W3169466414 hasAuthorship W3169466414A5069880463 @default.
• W3169466414 hasConcept C126322002 @default.
• W3169466414 hasConcept C203014093 @default.
• W3169466414 hasConcept C2522874641 @default.
• W3169466414 hasConcept C2776408679 @default.
• W3169466414 hasConcept C2776455275 @default.
• W3169466414 hasConcept C2780559512 @default.
• W3169466414 hasConcept C2994217296 @default.
• W3169466414 hasConcept C3020491458 @default.
• W3169466414 hasConcept C71924100 @default.
• W3169466414 hasConcept C90924648 @default.
• W3169466414 hasConceptScore W3169466414C126322002 @default.
• W3169466414 hasConceptScore W3169466414C203014093 @default.
• W3169466414 hasConceptScore W3169466414C2522874641 @default.
• W3169466414 hasConceptScore W3169466414C2776408679 @default.
• W3169466414 hasConceptScore W3169466414C2776455275 @default.
• W3169466414 hasConceptScore W3169466414C2780559512 @default.
• W3169466414 hasConceptScore W3169466414C2994217296 @default.
• W3169466414 hasConceptScore W3169466414C3020491458 @default.
• W3169466414 hasConceptScore W3169466414C71924100 @default.
• W3169466414 hasConceptScore W3169466414C90924648 @default.
• W3169466414 hasIssue "9" @default.
• W3169466414 hasLocation W31694664141 @default.
• W3169466414 hasOpenAccess W3169466414 @default.
• W3169466414 hasPrimaryLocation W31694664141 @default.
• W3169466414 hasRelatedWork W1972988087 @default.
• W3169466414 hasRelatedWork W2002226569 @default.
• W3169466414 hasRelatedWork W2072481799 @default.

• next